BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26125303)

  • 1. The Prognostic Significance of c-MET and EGFR Overexpression in Resected Gastric Adenocarcinomas.
    Paliga A; Marginean H; Tessier-Cloutier B; Purgina B; Jonker D; Marginean EC
    Am J Clin Oncol; 2017 Dec; 40(6):543-551. PubMed ID: 26125303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas.
    Petrini I; Lencioni M; Vasile E; Fornaro L; Belluomini L; Pasquini G; Ginocchi L; Caparello C; Musettini G; Vivaldi C; Caponi S; Ricci S; Proietti A; Fontanini G; Naccarato AG; Nardini V; Santi S; Falcone A
    Cancer Biomark; 2018 Feb; 21(3):731-741. PubMed ID: 29278885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MET gene copy number gain is an independent poor prognostic marker in Korean stage I lung adenocarcinomas.
    Jin Y; Sun PL; Kim H; Seo AN; Jheon S; Lee CT; Chung JH
    Ann Surg Oncol; 2014 Feb; 21(2):621-8. PubMed ID: 24212721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Significance of C-MET Overexpression and Epidermal Growth Factor Receptor Mutation in Platinum-Based Adjuvant Chemotherapy Outcome in Surgically Resected Lung Adenocarcinoma.
    Kim IH; Lee IH; Lee JE; Hong SH; Kim TJ; Lee KY; Kim YK; Kim SJ; Sung SW; Park JK; Yoo IR; Kim YS; Kim JO; Kang JH
    Ann Surg Oncol; 2017 Mar; 24(3):770-777. PubMed ID: 27696172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: a Danish cohort study.
    Erichsen R; Kelsh MA; Oliner KS; Nielsen KB; Frøslev T; Lænkholm AV; Vyberg M; Acquavella J; Sørensen HT
    Ann Epidemiol; 2016 Jul; 26(7):500-503. PubMed ID: 27318530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy.
    Ha SY; Lee J; Jang J; Hong JY; Do IG; Park SH; Park JO; Choi MG; Sohn TS; Bae JM; Kim S; Kim M; Kim S; Park CK; Kang WK; Kim KM
    Int J Cancer; 2015 Apr; 136(7):1629-35. PubMed ID: 25157953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment.
    Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
    J Clin Pathol; 2018 May; 71(5):451-462. PubMed ID: 29138285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The significance of NTR1 expression and its correlation with β-catenin and EGFR in gastric cancer.
    Zhou Z; Xie J; Cai Y; Yang S; Chen Y; Wu H
    Diagn Pathol; 2015 Jul; 10():128. PubMed ID: 26215716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.
    Park S; Choi YL; Sung CO; An J; Seo J; Ahn MJ; Ahn JS; Park K; Shin YK; Erkin OC; Song K; Kim J; Shim YM; Han J
    Histol Histopathol; 2012 Feb; 27(2):197-207. PubMed ID: 22207554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased MACC1 expression indicates a poor prognosis independent of MET expression in gastric adenocarcinoma.
    Koh YW; Hur H; Lee D
    Pathol Res Pract; 2016 Feb; 212(2):93-100. PubMed ID: 26719224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD151 overexpression is associated with poor prognosis in patients with pT3 gastric cancer.
    Ha SY; Do IG; Lee J; Park SH; Park JO; Kang WK; Choi MG; Lee JH; Bae JM; Kim S; Kim KM; Sohn TS
    Ann Surg Oncol; 2014 Apr; 21(4):1099-106. PubMed ID: 24306658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of major receptor tyrosine kinase expression in gastric cancer.
    Kurokawa Y; Matsuura N; Kawabata R; Nishikawa K; Ebisui C; Yokoyama Y; Shaker MN; Hamakawa T; Takahashi T; Takiguchi S; Mori M; Doki Y
    Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S584-90. PubMed ID: 24743909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.
    Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
    PLoS One; 2016; 11(2):e0148101. PubMed ID: 26844548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of pyruvate dehydrogenase is an independent prognostic marker in gastric cancer.
    Sun XR; Sun Z; Zhu Z; Guan HX; Li CY; Zhang JY; Zhang YN; Zhou H; Zhang HJ; Xu HM; Sun MJ
    World J Gastroenterol; 2015 May; 21(17):5336-44. PubMed ID: 25954108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma.
    Nagatsuma AK; Aizawa M; Kuwata T; Doi T; Ohtsu A; Fujii H; Ochiai A
    Gastric Cancer; 2015 Apr; 18(2):227-38. PubMed ID: 24626858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of EGFR as an Independent Prognostic Factor in Adenocarcinoma of the Esophagogastric Junction.
    Aratani K; Komatsu S; Ichikawa D; Ohashi T; Miyamae M; Okajima W; Imamura T; Kiuchi J; Nishibeppu K; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
    Anticancer Res; 2017 Jun; 37(6):3129-3135. PubMed ID: 28551654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and clinical significance of epidermal growth factor receptor and insulin-like growth factor receptor 1 in patients with ampullary adenocarcinoma.
    Xia M; Overman MJ; Rashid A; Chatterjee D; Wang H; Katz MH; Fleming JB; Lee JE; Varadhachary GR; Wolff RA; Wang H
    Hum Pathol; 2015 Sep; 46(9):1315-22. PubMed ID: 26165226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR2, HER2 and cMet in gastric adenocarcinoma: detection, prognostic significance and assessment of downstream pathway activation.
    Betts G; Valentine H; Pritchard S; Swindell R; Williams V; Morgan S; Griffiths EA; Welch I; West C; Womack C
    Virchows Arch; 2014 Feb; 464(2):145-56. PubMed ID: 24306956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
    He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
    J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.